This slim paperback presents, in a condensed form, the most important facets of current knowledge about causes and treatment of violence. Epidemiology, genetics, and neurobiology of violence are reviewed. The book was developed primarily for prescribers specializing in psychiatry, and most of the text is concerned with psychopharmacology of violence. Detailed theoretical information, including pharmacokinetics and molecular mechanisms of action, is provided for agents used in the treatment of violence. Dosing and adverse effects are also covered.
Particular attention is focused on the subpopulation of patients who are persistently aggressive and treatment resistant. This is a small but clinically challenging group. The authors build a theoretical rationale for using either high-dose antipsychotic (AP) monotherapy or polypharmacy in such patients. When they say highdose, they really mean it: for example, for olanzapine, it is 80 mg/day (the maximum dose recommended by the manufacturer and approved for marketing is 20 mg/day). They state, appropriately, that the dosing of APs above standard therapeutic levels warrants informed consent and increased patient monitoring. More information, including some limited evidence supporting this type of treatment, can be found elsewhere.
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The book differs from other available materials on this topic by its full-colour schematic images that illustrate each paragraph of the text. Each paragraph describes relation between catechol-O-methyltransferase (COMT) gene, polymorphism, and aggression. Each paragraph and its illustration are presented on a single page. This arrangement makes for easy reading. It also results in an unusual allocation of space. Thus clozapine, the gold standard of anti-aggressive medications, is given the same space (1 page) as drugs whose anti-aggressive effects have yet to be fully demonstrated.
The book is written quite concisely and the text is simple to understand. The authors are competent in neurobiological, genetic, and particularly in psychopharmacological aspects of violence. Overall, the In the last decade, child and adolescent psychiatry has progressed tremendously in the standardization of clinical assessment and treatment. Much effort has been dedicated to generate robust empirical evidence to support treatments and interventions, leading to a sizable body of literature, yet there remains skepticism and even downright antipathy to some of these interventions such as electroconvulsive therapy (ECT). These negative opinions people is worsened to some extent by the paucity of large randomized clinical trials and major issues around stigma and ethics despite the publication of practice parameters for the use of ECT in adolescents in 2004. The decision whether ECT is clinically indicated should to the individual, including the risks associated with the anesthetic, current comorbidities, anticipated adverse events such as cognitive impairment, and the risks of not having treatment.
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This book consists of 12 chapters written by internationally renowned experts at the forefront of research and clinical use of ECT. The chapters on the history of ECT, the role of stigma, ethical aspects, and the guide to using ECT in minors present a balanced view of the clinical utility and adverse effects of its use in children and adolescents. The authors review epidemiologic data, people, and suggest clinical strategies that are entirely relevant to current clinical practice. Each chapter starts with key points and ends with self-assessment questions.
